Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
Last trade$9.34
Day change+$0.21 (+2.30%)
Day range$9.04 – $9.49
Volume1,151,730
Market cap$822M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$821.96M
Price / earnings
—
Price / book
-47.84×
Price / sales
2.84×
EV / sales
3.21×
EV / EBITDA
-5.6×
Profitability
Earnings per share
-$2.33
Return on assets
-30.24%
Return on equity
1,219.34%
Dividend yield
0%
Liquidity and leverage
Debt / equity
-14.25×
Current ratio
4.69×
Quick ratio
4.37×
Cash ratio
1.12×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$177.55M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for SNDX, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$83.3M
$72.79M
$64.86M
$68.73M
$45.87M
$37.96M
$20.04M
$7.68M
Cost of revenue
$14M
$3.21M
$2.63M
$2.71M
$2.1M
$1.28M
$885K
$826K
Gross profit
$69.3M
$69.58M
$62.23M
$66.02M
$43.77M
$36.68M
$19.16M
$6.85M
Selling, general and administrative
$43.72M
$41.54M
$37.59M
$49.93M
$44.92M
$43.81M
$41.03M
$37.69M
Research and development
$67.48M
$68.04M
$58.85M
$78.64M
$56.28M
$62.23M
$61.64M
$65.53M
Total operating expenses
$111.2M
$109.58M
$108.28M
$104.38M
$101.2M
$106.03M
$110.96M
$103.22M
Operating income
-$41.9M
-$40M
-$46.05M
-$38.36M
-$57.43M
-$69.35M
-$91.81M
-$96.37M
Interest expense
-$1.17M
-$12.68M
$0
$0
$0
-$7.86M
-$2K
$124K
Income before taxes
-$49.43M
-$49.36M
-$42.67M
-$68.01M
-$60.72M
-$71.85M
-$84.85M
-$94.17M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$49.43M
-$49.36M
-$42.67M
-$68.01M
-$60.72M
-$71.85M
-$84.85M
-$94.17M
Net income attributable to common shareholders
-$49.43M
-$49.36M
-$42.67M
-$68.01M
-$60.72M
-$71.85M
-$84.85M
-$94.17M
EBITDA
-$41.89M
-$39.99M
-$46.04M
-$38.36M
-$57.42M
-$69.35M
-$91.56M
-$96.37M
Basic earnings per share
-$0.55
-$0.55
-$0.48
-$0.78
-$0.70
-$0.83
-$0.98
-$1.09
Diluted earnings per share
-$0.55
-$0.55
-$0.48
-$0.78
-$0.70
-$0.83
-$0.98
-$1.09
Recent news
Company coverage with links to the original publishers.
Syndax Pharmaceuticals reported a Q3 loss of $0.55 per share, missing EPS expectations by 5.77%, though it beat revenue estimates with $83.3 million (up 81.5% year-over-year). The stock has underperformed the market by 45.7% year-to-date and carries a Zacks Rank #3 (Hold) rating with mixed estimate revisions.
Syndax Pharmaceuticals announced that CEO Michael A. Metzger and management team members will participate in four major investor conferences in November 2026, including events hosted by Guggenheim, Stifel, UBS, and Jefferies. Live webcasts of the fireside chats will be available on the company's website.
Niagen Bioscience is expected to report Q3 2026 earnings on November 4 with a projected loss of $0.01 per share and revenues declining 11.3% year-over-year to $30.15 million. The company has a negative Earnings ESP of -500% and Zacks Rank #4, making it unlikely to beat consensus estimates. The stock does not appear to be a compelling earnings-beat candidate.
Syndax Pharmaceuticals is expected to report a quarterly loss of $0.52 per share for Q3 2026, representing a 25.7% year-over-year increase in losses, though revenues are projected to grow 76.8% to $81.09 million. With a negative Earnings ESP of -2.91% and a Zacks Rank #3 (Hold), the stock is not considered a compelling earnings-beat candidate. The company has a mixed track record, beating consensus estimates in only 2 of the last 4 quarters.
Syndax Pharmaceuticals announced it will report Q3 2026 financial results and host a conference call on November 2, 2026. The company is a commercial-stage biopharmaceutical firm with FDA-approved cancer therapies including Revuforj® (revumenib), a menin inhibitor, and Niktimvo™ (axatilimab-csfr), a CSF-1 receptor blocking monoclonal antibody.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.